Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CT Contrast Clear all
Completed Not applicable Interventional

Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan

NCT01843426
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Nov 4, 2026, 3:12 AM EST
Completed Not applicable Interventional

CT Scan Using IV Contrast Alone for Pediatric Appendicitis

NCT00716703
View directory record Official record
Conditions
Appendicitis, Child, Contrast Media
Interventions
CT Scan using IV contrast alone
Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2008 · Synced Nov 4, 2026, 3:12 AM EST
Not yet recruiting Not applicable Interventional

CaRi-Heart Assessment of Risk and Evaluation of Inflammation in Coronary CT Angiography (CARE-CCTA)

NCT07220304
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Cardiovascular Inflammation
Interventions
CaRi-Heart® Analysis
Device
Lead sponsor
Corazon Medical PC
Other
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Bay City, Michigan • Berkley, Michigan • Caro, Michigan + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 4, 2026, 3:12 AM EST
Recruiting Phase 2 Interventional

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
347
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 238 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Completed Not applicable Interventional

Pilot Study of High Risk Lung Cancer Screening

NCT03683940
View directory record Official record
Conditions
Lung Cancer
Interventions
Screening
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Nov 4, 2026, 3:12 AM EST
Recruiting Not applicable Interventional

Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies

NCT02043691
View directory record Official record
Conditions
Juxtarenal Aortic Aneurysm, Suprarenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Penetrating Aortic Ulcer, Aortic Arch Aneurysm, Aortic Dissection
Interventions
Cook Custom Aortic Endograft, Zenith t-Branch Endovascular Graft, Surgeon-Modified Endograft
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
View directory record Official record
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Not listed Early Phase 1 Interventional

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

NCT04315584
View directory record Official record
Conditions
Glioblastoma
Interventions
Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa
Procedure · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Nov 4, 2026, 3:12 AM EST
Completed Phase 2 Interventional Results available

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

NCT03081884
View directory record Official record
Conditions
Cancer
Interventions
FACBC PET-CT Imaging
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Nov 4, 2026, 3:12 AM EST
Completed Early Phase 1 Interventional

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

NCT04310540
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Biopsy, Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 4, 2026, 3:12 AM EST
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Nov 4, 2026, 3:12 AM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis

NCT04762719
View directory record Official record
Conditions
Diabetes, Gastroparesis With Diabetes Mellitus
Interventions
PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 4, 2026, 3:12 AM EST
Recruiting Not applicable Interventional

Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics

NCT06523166
View directory record Official record
Conditions
Device Related Thrombosis, Peri-device Leak
Interventions
Transesophageal echocardiography (TEE), Cardiac CTA
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Roslyn, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Active, not recruiting Phase 2 Interventional Results available

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

NCT04739800
View directory record Official record
Conditions
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
384
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Terminated Not applicable Interventional

Viability Imaging in Volumetric Angiography (VIVA 1)

NCT01408134
View directory record Official record
Conditions
Myocardial Scarring
Interventions
DE CT
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Nov 4, 2026, 3:12 AM EST
Active, not recruiting Not applicable Interventional

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

NCT04454450
View directory record Official record
Conditions
Ovarian Cancer, High Grade Ovarian Serous
Interventions
PET/MRI, Contrast enhanced CT
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Terminated Not applicable Interventional Results available

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

NCT01799135
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
DCE-MRI scan, Stereotactic Body Radiation Therapy, 4D-CT scan
Other · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 4, 2026, 3:12 AM EST
Not yet recruiting No phase listed Observational

Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization

NCT07768046
View directory record Official record
Conditions
Solitary Pulmonary Nodule, Multiple Pulmonary Nodules, Lung Neoplasms, Lung Cancer Screening
Interventions
Multiparametric chest MRI with diffusion-weighted imaging
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Recruiting Phase 1 Interventional

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

NCT05136846
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy, Pemetrexed, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging of the Brain with and without Contrast, Biospecimen Collection
Drug · Biological · Radiation + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Duarte, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Terminated Phase 1 Interventional Results available

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

NCT04504331
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions
Infigratinib, Tamoxifen, Omnipaque 350, Iopamidol, Computed tomography (CT)
Drug · Diagnostic Test
Lead sponsor
Jennifer Lee Caswell-Jin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 4, 2026, 3:12 AM EST
Recruiting No phase listed Observational

Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry

NCT06075628
View directory record Official record
Conditions
Atrial Fibrillation, Ischemic Stroke, Acute
Interventions
Left Atrial Appendage Occlusion
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Nov 4, 2026, 3:12 AM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964
View directory record Official record
Conditions
Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Nov 4, 2026, 3:12 AM EST
Completed Early Phase 1 Interventional

NIH CCR2 AAA Study

NCT04586452
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
Interventions
AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A), Relationship between radiotracer and CCR2 (Aim 2B), AAA Group (Aim 3B-Reproducibility)
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 4, 2026, 3:12 AM EST
Terminated No phase listed Observational Results available

Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route

NCT01531686
View directory record Official record
Conditions
Patients With Intraosseous Vascular Access Requiring Computed Tomography (CT) Exam
Interventions
Intraosseous delivery of CT contrast dye
Procedure
Lead sponsor
Vidacare Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Phoenix, Arizona • Sylmar, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 4, 2026, 3:12 AM EST